Long-term psoriasis drug shows sustained benefit in extended trial data

Bimekizumab maintained its effectiveness and safety profile over two years in patients with moderate to severe plaque psoriasis, according to interim results from the BE RADIANT trial. The finding could influence treatment guidelines and market positioning for this biologic therapy in a competitive psoriasis drug market.

Originaltitel: Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial